Granulocytic myeloid-derived suppressor cell population increases with the severity of alcoholic liver disease.
Adult
Aged
Aged, 80 and over
Apoptosis
/ physiology
Carcinoma, Hepatocellular
/ pathology
Female
Granulocytes
/ pathology
Hepatic Stellate Cells
/ pathology
Humans
Killer Cells, Natural
/ pathology
Liver
/ pathology
Liver Diseases, Alcoholic
/ pathology
Liver Neoplasms
/ pathology
Male
Middle Aged
Myeloid-Derived Suppressor Cells
/ pathology
Prognosis
Young Adult
alcoholic liver disease
arginase
myeloid-derived suppressor cells
severity
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
13
05
2018
revised:
24
08
2018
accepted:
03
12
2018
pubmed:
27
12
2018
medline:
26
6
2020
entrez:
27
12
2018
Statut:
ppublish
Résumé
Alcoholic liver disease (ALD) is a progressive liver disease that can cause a series of complications, including cirrhosis, liver failure and hepatocellular carcinoma. Granulocytic myeloid-derived suppressor cell (gMDSC) populations have been observed to expand in various liver diseases and to inhibit innate and adaptive immunity in patients with liver disease. However, the characteristics of gMDSCs in patients with ALD have not been studied. We studied 24 healthy controls (HCs) and 107 patients with ALD and found an accumulation of gMDSCs in the peripheral blood of patients with alcoholic liver cirrhosis (ALC). Furthermore, ALC patients with a poor prognosis displayed a significant increase in peripheral gMDSCs and showed an increased capacity for arginase I production compared to HCs. In contrast, plasma arginase I levels in ALC patients were negatively correlated with total bilirubin and international normalized ratio, two key parameters of liver damage. Importantly, gMDSCs accumulated in the livers of ALC patients, and the frequency of liver gMDSCs significantly correlated with that of peripheral gMDSCs. In addition, gMDSC enrichment in vitro significantly inhibited the function of natural killer (NK) cells, perhaps preventing the NK-induced apoptosis of hepatic stellate cells. In summary, increased peripheral and intrahepatic gMDSC populations are present in patients with ALC and may contribute to enhancing the severity of liver cirrhosis.
Identifiants
pubmed: 30585398
doi: 10.1111/jcmm.14109
pmc: PMC6378203
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2032-2041Informations de copyright
© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Références
Gastroenterology. 2011 Nov;141(5):1572-85
pubmed: 21920463
PLoS One. 2011 Mar 01;6(3):e17484
pubmed: 21390263
Cancer Res. 2013 Apr 15;73(8):2435-44
pubmed: 23423978
J Immunol. 2008 Sep 1;181(5):3049-56
pubmed: 18713975
Hepatology. 2008 Oct;48(4):1224-31
pubmed: 18792393
Cancer Immunol Immunother. 2016 Jun;65(6):715-25
pubmed: 27083166
Gastroenterology. 2004 Sep;127(3):870-82
pubmed: 15362042
Nat Med. 2015 Jun;21(6):591-600
pubmed: 25962123
J Immunol. 2014 Dec 1;193(11):5461-9
pubmed: 25344470
J Clin Gastroenterol. 2009 Feb;43(2):182-90
pubmed: 18633332
J Immunol. 2007 Jul 15;179(2):977-83
pubmed: 17617589
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947
Mol Cells. 2014 Jan;37(1):66-73
pubmed: 24552712
Alcohol Clin Exp Res. 2011 May;35(5):787-93
pubmed: 21284667
Hepatology. 2006 Dec;44(6):1441-51
pubmed: 17133483
J Hepatol. 2009 Jun;50(6):1258-66
pubmed: 19398236
Hepatology. 2013 May;57(5):2078-80
pubmed: 23609413
J Clin Immunol. 2013 May;33(4):798-808
pubmed: 23354838
Front Immunol. 2017 Oct 30;8:1414
pubmed: 29163491
Hepatology. 2018 Jan;67(1):232-246
pubmed: 28777871
Hepatology. 2012 Feb;55(2):343-53
pubmed: 21953144
Alcohol Clin Exp Res. 2014 Apr;38(4):1035-41
pubmed: 24428769
J Cell Mol Med. 2019 Mar;23(3):2032-2041
pubmed: 30585398
Medicine (Baltimore). 2016 Feb;95(8):e2877
pubmed: 26937922
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s
pubmed: 17255300
Cancer Res. 2010 Jan 1;70(1):68-77
pubmed: 20028852
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
J Hepatol. 2013 Jul;59(1):160-8
pubmed: 23511777
PLoS One. 2016 Feb 22;11(2):e0149948
pubmed: 26901500
Am J Gastroenterol. 2010 Jan;105(1):14-32; quiz 33
pubmed: 19904248
Cancer Res. 2009 Feb 15;69(4):1553-60
pubmed: 19201693
Nat Immunol. 2012 Sep;13(9):843-50
pubmed: 22863752
Hepatology. 2009 Sep;50(3):799-807
pubmed: 19551844
Immunology. 2016 Aug;148(4):377-86
pubmed: 27149428
J Immunol. 2004 Jan 15;172(2):989-99
pubmed: 14707072
J Dig Dis. 2011 Feb;12(1):45-50
pubmed: 21276208
Front Immunol. 2017 Dec 12;8:1786
pubmed: 29312314
Gastroenterology. 2008 Jul;135(1):234-43
pubmed: 18485901
Front Immunol. 2016 Jan 29;7:19
pubmed: 26858722